FOLH1 and Familial prostate cancer: PSMA is a novel and promising target for diagnostics and therapy of metastatic prostate cancer, especially when the androgen receptor is the persistent therapeutic target and pending cross resistances might occur in subsequent androgen-directed therapies [30].